Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cytotoxic agent-LAT1 substrate QBS10072S

A blood-brain-barrier (BBB) penetrative agent composed of a cytotoxic chemotherapeutic domain, tertiary N-bis(2-chloroethyl)amine, linked to the structural features of a selective large amino acid transporter 1 (LAT1) substrate, with potential antineoplastic activity. Upon administration of QBS10072S, the LAT1 substrate binds to LAT1 expressed on the BBB and in LAT1-expressing cancer cells, such as glioblastoma multiforme (GBM). After entering the brain and binding to LAT1-expressing tumor cells, the cytotoxic domain in turn binds to DNA, causing cell cycle arrest and induces apoptosis. LAT1 is expressed at much lower levels in normal brain tissue and QBS10072S may therefore potentially target brain tumors while avoiding uptake by healthy, normal tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:QBS 10072S
QBS 72S
QBS-10072S
QBS-72S
QBS10072S
QBS72S
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search